|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical application of next-generation sequencing-based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies.
|
31826932 |
2020 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, the BRAF inhibitor vemurafenib has been successfully established in the therapy of advanced melanoma.
|
31269229 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.
|
30422243 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review focuses on pre-clinical studies and early to phase III clinical trials to discuss the development of combined therapy based on BRAF inhibitors for BRAF-mutant advanced melanoma, as well as mechanisms of resistance to BRAF inhibitors.
|
31514399 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
|
30939167 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review aims to evaluate the role of BRAF-targeted therapy for advanced melanoma in the immunotherapy era.
|
31359162 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Approximately, one half of advanced melanoma bears a mutation in the BRAF gene that makes BRAF as an important therapeutic target.
|
30778775 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study found that hybrid capture-based next-generation sequencing can detect BRAF alterations in samples from a significant fraction of patients with advanced melanoma with prior negative BRAF results.
|
30683711 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future strategies for the treatment of advanced melanoma include novel combination therapies using BRAF/MEK inhibitors and immune checkpoints inhibitors or histone deacetylase inhibitors.
|
30556435 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PLX4032 is commonly used in the treatment of advanced melanoma patients with BRAF-V600E mutation.
|
31810919 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No difference was recorded in OS by brain metastases (log-rank P = .22) or BRAF mutation status (log-rank P = .90).These findings support effectiveness of pembrolizumab in the real-world clinical setting and provide important insights into patient characteristics and outcomes associated with pembrolizumab therapy for a heterogeneous patient population with advanced melanoma, including patients who would not be eligible for clinical trials.
|
31348273 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glembatumumab vedotin had modest activity and an acceptable safety profile in patients with advanced melanoma who were refractory to checkpoint inhibitors and MEK/BRAF inhibition.
|
30690710 |
2019 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings highlight the efficacy of combination PD-1 with CTLA-4 inhibitors and combination BRAF with MEK inhibitors in the treatment of advanced melanoma.
|
30798169 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
|
30563395 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
|
30852924 |
2019 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
|
29232304 |
2018 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
|
29970025 |
2018 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These were: (1) whether complete lymph node dissection should be routinely offered to all melanoma patients with sentinel lymph node-positive disease; (2) whether first-line treatment of BRAF-mutated melanoma should consist of BRAF-targeted therapy or immunotherapy with checkpoint inhibitors; and (3) whether combined or sequential administration of treatments should be the preferred option in the management of patients with advanced melanoma.
|
29665799 |
2018 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As there are few second-line treatment options for patients with BRAF wild-type advanced melanoma after nivolumab failure, patients should be closely monitored if ipilimumab is initiated.
|
29079332 |
2018 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the efficacy of BRAF inhibitor-based combination therapy for the treatment of advanced melanoma with BRAF mutation.
|
28504036 |
2018 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combination of dabrafenib and trametinib demonstrated encouraging antitumor activity and tolerability, at initial analysis, in Japanese patients with BRAF V600 mutant advanced melanoma warranting further investigation.
|
29399853 |
2018 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Development of encorafenib for BRAF-mutated advanced melanoma.
|
29356698 |
2018 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By now, BRAF inhibition is the standard therapy for advanced melanoma in patients carrying BRAF mutations.
|
29059159 |
2018 |
|
Advanced Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
|
30175642 |
2018 |
|
Advanced Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vemurafenib improves the management of advanced melanoma due to selective inhibition of the mutated BRAF V600E kinase.
|
29485438 |
2018 |